Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

Journal article

Peer reviewed

Alexander J. Rossi, Tahsin M. Khan, Hanna Hong, Gregory B. Lesinski, Christina Wu and Jonathan M. Hernandez

Annals of surgical oncology, Vol.28(8), pp.4098-4099

08/01/2021

DOI: 10.1245/s10434-021-10111-0

PMID: 33987757

View Online

no abstract

Oncology

Surgery

Surgical Oncology

ASO Research Letter

Medicine

Medicine & Public Health

Title: Subtitle: Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer
Creators: Alexander J. Rossi - National Institutes of Health
Tahsin M. Khan - National Institutes of Health
Hanna Hong - National Institutes of Health
Gregory B. Lesinski - Emory University
Christina Wu - Emory University
Jonathan M. Hernandez - National Institutes of Health
Resource Type: Journal article
Publication Details: Annals of surgical oncology, Vol.28(8), pp.4098-4099
DOI: 10.1245/s10434-021-10111-0
PMID: 33987757
NLM abbreviation: Ann Surg Oncol
ISSN: 1068-9265
eISSN: 1534-4681
Publisher: Springer International Publishing
Number of pages: 2
Language: English
Date published: 08/01/2021
Academic Unit: Surgery
Record Identifier: 9985224318302771

2 Record Views